{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:15:38Z","timestamp":1791497738899,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-186189"],"award-info":[{"award-number":["PJT-186189"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020951","name":"Fonds de recherche du Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de recherche du Quebec Sante","doi-asserted-by":"publisher","award":["288558"],"award-info":[{"award-number":["288558"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.conb.2025.103140","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:32:26Z","timestamp":1763631146000},"page":"103140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective"],"prefix":"10.1016","volume":"95","author":[{"given":"Danielle M.","family":"Simons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3371","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Trempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2025.103140_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.conb.2025.103140_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_bib5","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023487118","article-title":"The N terminus of \u03b1-synuclein dictates fibril formation","volume":"118","author":"McGlinchey","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.conb.2025.103140_bib6","doi-asserted-by":"crossref","first-page":"11113","DOI":"10.1073\/pnas.1903049116","article-title":"Functional cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling","volume":"116","author":"Sun","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.conb.2025.103140_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110675","article-title":"Synaptic vesicle binding of \u03b1-synuclein is modulated by \u03b2- and \u03b3-synucleins","volume":"39","author":"Carnazza","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.conb.2025.103140_bib8","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1038\/s41467-023-39843-1","article-title":"Elevated concentrations cause upright alpha-synuclein conformation at lipid interfaces","volume":"14","author":"Roeters","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","article-title":"Structures of \u03b1-synuclein filaments from human brains with Lewy pathology","volume":"610","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312306120","article-title":"Lysophagy protects against propagation of \u03b1-synuclein aggregation through ruptured lysosomal vesicles","volume":"121","author":"Kakuda","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103140_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2487","article-title":"Determinants of seeding and spreading of \u03b1-synuclein pathology in the brain","volume":"6","author":"Henrich","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_sref12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1126\/science.adp3645","article-title":"Neuronal FAM171A2 mediates \u03b1-synuclein fibril uptake and drives Parkinson's disease","volume":"387","author":"Wu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_sref13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.str.2022.11.013","article-title":"Conformational change of \u03b1-synuclein fibrils in cerebrospinal fluid from different clinical phases of Parkinson's disease","volume":"31","author":"Fan","year":"2023","journal-title":"Structure"},{"key":"10.1016\/j.conb.2025.103140_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of \u03b1-synuclein filaments from multiple system atrophy","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_sref15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41589-024-01551-2","article-title":"O-GlcNAc forces an \u03b1-synuclein amyloid strain with notably diminished seeding and pathology","volume":"20","author":"Balana","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.conb.2025.103140_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","article-title":"\u03b1-Synuclein strains target distinct brain regions and cell types","volume":"23","author":"Lau","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.conb.2025.103140_bib17","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","article-title":"\u03b1-Synuclein aggregates amplified from patient-derived lewy bodies recapitulate lewy body diseases in mice","volume":"14","author":"Uemura","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib18","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2025.103140_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2025.103140_bib20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/mds.29170","article-title":"Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-Synuclein misfolding, including a randomized study in parkinson's disease","volume":"37","author":"Smit","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103140_bib21","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_sref22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41589-024-01580-x","article-title":"Discovery of potent inhibitors of \u03b1-synuclein aggregation using structure-based iterative learning","volume":"20","author":"Horne","year":"2024","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.conb.2025.103140_bib23","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-024-47585-x","article-title":"Pharmacological inhibition of \u03b1-synuclein aggregation within liquid condensates","volume":"15","author":"Dada","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426745122","article-title":"Targeted degradation of \u03b1-Synuclein using an evolved botulinum toxin protease","volume":"122","author":"Sondermann","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103140_bib25","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.conb.2025.103140_bib26","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.1021\/acs.jmedchem.3c00235","article-title":"Nonpeptidic oxazole-based prolyl oligopeptidase ligands with disease-modifying effects on \u03b1-Synuclein mouse models of parkinson's disease","volume":"66","author":"Kilpel\u00e4inen","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.conb.2025.103140_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.conb.2025.103140_bib28","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.cell.2021.05.004","article-title":"Structural analysis of the full-length human LRRK2","volume":"184","author":"Myasnikov","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.conb.2025.103140_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson's disease and model for microtubule interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.conb.2025.103140_bib31","doi-asserted-by":"crossref","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","article-title":"Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-Synuclein gene-induced neurodegeneration","volume":"290","author":"Daher","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.conb.2025.103140_bib32","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ structure of Parkinson's disease-linked LRRK2","volume":"182","author":"Watanabe","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.conb.2025.103140_sref33","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202310150","article-title":"A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes","volume":"224","author":"Bentley-DeSousa","year":"2025","journal-title":"J Cell Biol"},{"key":"10.1016\/j.conb.2025.103140_sref34","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.adi9926","article-title":"Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2","volume":"382","author":"Zhu","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_bib35","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.1038\/s41467-024-52723-6","article-title":"RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib36","first-page":"1","article-title":"Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.conb.2025.103140_sref37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk6191","article-title":"Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Sanz Murillo","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_bib38","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-Synuclein inclusion formation in a parkinson's disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.conb.2025.103140_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.conb.2025.103140_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106906","article-title":"Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease","volume":"141","author":"Cao","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.conb.2025.103140_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103140_sref42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt2050","article-title":"Type II kinase inhibitors that target Parkinson's disease-associated LRRK2","volume":"11","author":"Raig","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.conb.2025.103140_bib44","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multi-center analysis of glucocerebrosidase mutations in Parkinson disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2025.103140_bib45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.26166","article-title":"Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and \u03b1-Synuclein mutations","volume":"90","author":"Jo","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2025.103140_bib46","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-Synuclein and glycolipid levels in iPSC-Derived dopaminergic neurons from patients with gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2025.103140_bib47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12883-024-03629-9","article-title":"Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation","volume":"24","author":"Siemeling","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.conb.2025.103140_bib48","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/hmg\/ddac038","article-title":"Ambroxol reverses tau and \u03b1-synuclein accumulation in a cholinergic N370S GBA1 mutation model","volume":"31","author":"Yang","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.conb.2025.103140_bib49","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.conb.2025.103140_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells","volume":"82","author":"Ambrosi","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2025.103140_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/mds.29346","article-title":"A phase 1B trial in -Associated Parkinson's disease of BIA-28-6156, a glucocerebrosidase activator","volume":"38","author":"den Heijer","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103140_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","article-title":"Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.conb.2025.103140_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.conb.2025.103140_bib54","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1002\/anie.202013890","article-title":"Novel \u03b2-Glucocerebrosidase activators that bind to a new pocket at a dimer interface and induce dimerization","volume":"60","author":"Benz","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.conb.2025.103140_bib55","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1021\/jacs.7b13003","article-title":"\u03b2-Glucocerebrosidase modulators promote dimerization of \u03b2-Glucocerebrosidase and reveal an allosteric binding site","volume":"140","author":"Zheng","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.conb.2025.103140_sref56","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.1021\/acs.jmedchem.4c00702","article-title":"Fragment-based discovery of a series of allosteric-binding site modulators of \u03b2-Glucocerebrosidase","volume":"67","author":"Palmer","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.conb.2025.103140_bib57","article-title":"Identification of \u00df-Glucocerebrosidase activators for glucosylceramide hydrolysis","volume":"19","author":"Schulze","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.conb.2025.103140_sref58","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41467-025-58340-1","article-title":"Cryo-TEM structure of \u03b2-glucocerebrosidase in complex with its transporter LIMP-2","volume":"16","author":"Dobert","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.11.015","article-title":"Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics","volume":"73","author":"Senkevich","year":"2020","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.conb.2025.103140_bib60","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41556-024-01513-9","article-title":"The role of PINK1-Parkin in mitochondrial quality control","volume":"26","author":"Narendra","year":"2024","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.conb.2025.103140_bib61","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.1237908","article-title":"Structure of parkin reveals mechanisms for ubiquitin ligase activation","volume":"340","author":"Trempe","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_bib62","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molcel.2021.11.012","article-title":"Mechanism of PINK1 activation by autophosphorylation and insights into assembly on the TOM complex","volume":"82","author":"Rasool","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.conb.2025.103140_bib63","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41586-018-0448-9","article-title":"Parkin and PINK1 mitigate STING-induced inflammation","volume":"561","author":"Sliter","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","article-title":"Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-\/- mice","volume":"571","author":"Matheoud","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313540121","article-title":"Tom20 gates PINK1 activity and mediates its tethering of the TOM and TIM23 translocases upon mitochondrial stress","volume":"121","author":"Eldeeb","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103140_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112454","article-title":"TIM23 facilitates PINK1 activation by safeguarding against OMA1-mediated degradation in damaged mitochondria","volume":"42","author":"Akabane","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.conb.2025.103140_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn7191","article-title":"Mechanism of human PINK1 activation at the TOM complex in a reconstituted system","volume":"10","author":"Raimi","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_sref68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.adu6445","article-title":"Structure of human PINK1 at a mitochondrial TOM-VDAC array","volume":"388","author":"Callegari","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.conb.2025.103140_sref69","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1038\/s41467-024-51889-3","article-title":"Activation of parkin by a molecular glue","volume":"15","author":"Sauv\u00e9","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.conb.2025.103140_bib70","article-title":"Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase","volume":"25","author":"Shlevkov","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.conb.2025.103140_bib71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cell.2013.07.030","article-title":"A neo-substrate that amplifies catalytic activity of Parkinson\u2019s-Disease-Related kinase PINK1","volume":"154","author":"Hertz","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.conb.2025.103140_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj7408","article-title":"Interaction of PINK1 with nucleotides and kinetin","volume":"10","author":"Gan","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_bib73","article-title":"Pharmacological PINK1 activation ameliorates pathology in Parkinson's disease models","author":"Hertz","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.conb.2025.103140_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ady0240","article-title":"Putative PINK1\/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress","volume":"11","author":"Rosencrans","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2025.103140_bib75","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1038\/s41598-024-58285-3","article-title":"Identification and structural characterization of small molecule inhibitors of PINK1","volume":"14","author":"Rasool","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2025.103140_bib76","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature13418","article-title":"The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy","volume":"510","author":"Bingol","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.conb.2025.103140_bib77","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000768","article-title":"USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation","volume":"3","author":"Rusilowicz-Jones","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.conb.2025.103140_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002244","article-title":"FBXO7\/ntc and USP30 antagonistically set the ubiquitination threshold for basal mitophagy and provide a target for Pink1 phosphorylation in vivo","volume":"21","author":"Sanchez-Martinez","year":"2023","journal-title":"PLoS Biol"},{"key":"10.1016\/j.conb.2025.103140_sref79","doi-asserted-by":"crossref","DOI":"10.1038\/s41594-025-01534-4","article-title":"Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30","author":"Kazi","year":"2025","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.conb.2025.103140_bib80","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.stem.2016.07.005","article-title":"Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons","volume":"19","author":"Jo","year":"2016","journal-title":"Cell Stem Cell"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:30:52Z","timestamp":1780914652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438825001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":80,"alternative-id":["S0959438825001710"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2025.103140","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein mechanism and therapeutic design in Parkinson's disease: A structural biology perspective","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2025.103140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103140"}}